Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.75 |
| ▸ | TDO2 | P48775 | 8/20 | 0.75 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | EIF4A3 | P38919 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747188 | 1.00 | IDO1 (0.75) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL22394891 | 0.88 | IDO1 (0.65) | IDO1TDO2HRH4EIF4A3RHEB | |
| SCHEMBL20505032 | 0.88 | IDO1 (0.65) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL22396294 | 0.88 | IDO1 (0.65) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL24113200 | 0.85 | IDO1 (0.58) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL21725077 | 0.85 | HRH4 (0.59) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL30817219 | 0.85 | IDO1 (0.58) | IDO1TDO2EIF4A3HPGDKDM4E | |
| SCHEMBL24020852 | 0.85 | IDO1 (0.58) | IDO1TDO2EIF4A3HPGDKDM4E | |
| SCHEMBL30310603 | 0.85 | IDO1 (0.58) | IDO1TDO2HRH4EIF4A3HPGD | |
| SCHEMBL30056140 | 0.85 | HRH4 (0.59) | IDO1TDO2HRH4EIF4A3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024059087-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| CN-116348477-A | Functionalized peptides as antiviral agents | 英安塔制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023086350-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022244821-A1 | COMPOUND EXHIBITING PHYSIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY | 国立研究開発法人国立国際医療研究センター | 2022-11-24 | — | — | WO | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | IDO1 2565/4885TDO2 3925/4885HRH4 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.